The endogenous cellular and molecular mechanisms that control acute infl ammation and its resolution are of wide interest. Using self-resolving infl ammatory exudates and lipidomics, we have identifi ed a new pathway involving biosynthesis of potent antiinfl ammatory and proresolving mediators from the essential fatty acid docosahexaenoic acid (DHA) by macrophages (M ⌽ s). During the resolution of mouse peritonitis, exudates accumulated both 17hydroxydocosahexaenoic acid, a known marker of 17 S -D series resolvin (Rv) and protectin biosynthesis, and 14 S -hydroxydocosa-4 Z ,7 Z ,10 Z ,12 E ,16 Z ,19 Z -hexaenoic acid from endogenous DHA. Addition of either DHA or 14 S -hydroperoxydocosa-4 Z ,7 Z ,10 Z ,12 E ,16 Z ,19 Zhexaenoic acid to activated M ⌽ s converted these substrates to novel dihydroxy-containing products that possessed potent antiinfl ammatory and proresolving activity with a potency similar to resolvin E1, 5 S ,12 R ,18 R -trihydroxyeicosa- 6 Z ,8 E ,10 E ,14 Z ,16 E -pentaenoic acid,  and protectin D1, 10 R ,17 S -dihydroxydocosa-4 Z ,7 Z ,11 E ,13 E ,15 Z ,19 Z - hexaenoic acid. Stable isotope incorporation, intermediate trapping, and characterization of physical and biological properties of the products demonstrated a novel 14-lipoxygenase pathway, generating bioactive 7,14-dihydroxydocosa-4 Z ,8,10,12,16 Z ,19 Z -hexaenoic acid, coined M ⌽ mediator in resolving infl ammation (maresin), which enhances resolution. These fi ndings suggest that maresins and this new metabolome may be involved in some of the benefi cial actions of DHA and M ⌽ s in tissue homeostasis, infl ammation resolution, wound healing, and host defense.
Given the contribution of uncontrolled infl ammation to many human diseases, the identifi cation of endogenous control mechanisms in the acute infl ammatory response is of wide interest ( 1 ) . Classical lipid mediators such as the prostaglandins and leukotrienes are well appreciated for their important proinfl ammatory roles in infl ammation ( 2 ) . In recent years, the resolution of infl ammation has emerged as an area with considerable potential to contain local mediators that may be useful for new therapeutic approaches (for reviews see references 3, 4 ) . Using an unbiased systems approach using lipidomics, proteomics, and cell traffi cking to study self-resolving infl ammatory exudates revealed that the termination of acute infl ammation involves active biosynthetic processes producing novel endogenous lipid mediators that are both antiinfl ammatory and proresolving ( 5 -8 ) . It is now clear that resolution of acute infl ammation is an active rather than passive process, as previously understood ( 9 ) , generating novel potent counterregulatory mediators termed resolvins (Rvs) and protectins (for review see reference 4 ) .
Rvs and protectins are biosynthesized by exudates from essential omega-3 fatty acids (e.g., eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), and the structures are established for key members of these families ( 4 ) . The immune regulatory actions of omega-3 fatty acids and their roles in human health and diseases such as cancer and neuroinfl ammation are widely appreciated ( 10 -12 ) . Although omega-3 fatty acids are in wide use as dietary supplements These two LOX products were identifi ed by characteristic diagnostic ions in their respective mass spectra. Fig. 1 B shows a representative spectrum of 17-HDHA formed in the and potential therapeutics in many diseases, including infl ammatory diseases, their mechanisms and connection to infl ammation remain of interest. Rvs and protectins display potent multilevel antiinfl ammatory and proresolving actions ( 13 ) and are members of a new genus of endogenous mediators of resolution ( 4 ) . For example, resolvin E1, 5 S ,12 R ,18 R -trihydroxyeicosa-6 Z ,8 E ,10 E ,14 Z ,16 E -pentaenoic acid (RvE1) is bio synthesized from EPA and interacts with specifi c receptors to control infl ammatory cells ( 14, 15 ) . Also, fat-1 transgenic mice, producing higher endogenous levels of omega-3, show reduced infl ammatory status and elevated levels of Rvs and protectins, which when administered reduce infl ammation and stimulate resolution ( 16 -18 ) . The main biosynthetic route with DHA for Rvs and protectins proceeds during resolution via a 17 Shydroperoxydocosahexaenoic intermediate produced by a lipoxygenase (LOX) mechanism. With aspirin therapy, acetylated cyclooxygenase-2 produces aspirin-triggered 17 R -epimers of Rvs and protectins and also enhances their formation ( 6 ) . Genetic defi ciency or overexpression of mouse 12/15-LOX regulates production of Rvs and protectins, and alters their responses to both thermal injury and extent of atherosclerosis ( 17, 18 ) .
In this report, we present evidence for a new pathway of mediators operative in resolution of acute infl ammation that possess potent actions with polymorphonuclear neutrophils (PMNs) and macrophages (M ⌽ s). Identifi cation of these new mediators, coined M ⌽ mediators in resolving infl ammation (maresins), provides evidence for autacoids produced from essential omega-3 fatty acids by a new pathway that may be linked to homeostasis, infl ammation resolution, wound healing, and cancer.
RESULTS AND DISCUSSION Targeted lipidomics of resolving infl ammatory exudates
In view of the actions of specialized chemical mediators in resolution ( 6, 7 ), we monitored 17-hydroxydocosahexaenoic acid (17-HDHA) as a biomarker of activation and conversion of endogenous DHA, and also used targeted lipidomics to query whether other pathways were operative ( Fig. 1 ). During this course of peritonitis, PMNs rapidly entered, reaching maximum within 12 h. As expected in this self-resolving system ( 19 ) , PMNs declined and were lost from exudates, thus defi ning resolution ( Fig. 1 ). Unbiased targeted mediator lipidomics using liquid chromatography -tandem mass spectrometry (LC/MS/MS) -based analyses were performed with these exudates. In addition to 17 S -hydroxydocosa-4 Z ,7 Z ,10 Z ,13 Z ,15 E ,19 Z -hexaenoic acid, a marker of Rv and protectin biosynthesis ( 6 ), endogenous DHA was converted to 14 S -hydroxydocosa-4 Z ,7 Z ,10 Z ,12 E ,16 Z ,19 Zhexaenoic acid (14 S -HDHA). Neither product was identifi ed in exudates obtained with the LOX inhibitor esculetin ( n = 3), and both were substantially reduced in peritonitis lavages from 12/15-LOX -defi cient mice ( n = 2, d = 4). The appearance of 14 S -HDHA in this system accompanied 17-HDHA throughout the 72-h course, indicating that 14 S -HDHA accumulated within the resolution phase. 
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material showed remarkable antiinfl ammatory properties ( Fig. 3 A ) regulating PMN entry into zymosan-induced peritonitis when directly compared with other omega-3 fatty acidderived mediators such as neuroprotectin/protectin D1, 10 R , time course, and Fig. 1 C shows the spectrum of 14 S -HDHA, as well as diagnostic ions for identifi cation. These included mass-to-charge ratio (m/z) 205, 138, and 233, specifi c for 14 S -HDHA. The m/z 343 [M-H], and m/z 325, 299, and 281 ions are shared between 14-and 17-HDHA ( Fig. 1, B and C , insets). Both 14 S -HDHA and 17-HDHA were also generated from endogenous DHA with isolated mouse M ⌽ s activated with Ca 2+ ionophore A 23187 (5 μ M, pH 7.45, n = 4; representative values: 14 S -HDHA, 325 pg/10 6 cells, and 17-HDHA, 439 pg/10 6 cells). These results demonstrate that during the time course of acute infl ammation and its resolution, a sustained production of endogenous LOX products was present in the initial acute phase at 2 -4 h that accumulated during resolution with the highest levels of 14 S -HDHA > 17-HDHA at 72 h.
We reasoned that 14 S -HDHA might be a marker refl ecting activation of a novel DHA (C22:6) carbon 14lipoxygenation pathway. This could lead to production of bioactive mediators via DHA, because monohydroxy products of polyunsaturated fatty acids are biomarkers of pathways leading to potent bioactive molecules, as in the case of 17-HDHA and 17-HpDHA, precursors to Rvs and protectins ( 6, 20, 21 ) . Also, 5-hydroxyeicosatetraenoic acid is a well-appreciated marker of arachidonic acid conversion to leukotrienes ( 2 ) . To this end, resident peritoneal M ⌽ s were isolated ( Fig. 2 A , FACS inset), containing ‫ف‬ 85 -90% M ⌽ s and 10 -15% lymphocytes, and 14 S -hydroperoxydocosa-4 Z ,7 Z ,10 Z ,12 E ,16 Z ,19 Z -hexaenoic acid (14 S -HpDHA) was prepared via biogenic synthesis and incubated with these cells to determine whether it was a precursor to new bioactive products. 14 S -HpDHA was isolated from 12-LOX incubated with HPLC-purifi ed DHA ( n = 7) and was > 98% S confi guration determined by chiral LC/MS/MS. Both 14 S -HpDHA (10 μ M) and DHA (10 μ M) were converted by resident M ⌽ s to new products identifi ed via LC/MS/MS-based mediator lipidomics ( Fig. 2 A ) labeled I and II. Each had conjugated triene-containing UV chromophores, chromatographic behavior, and mass spectra consistent with 7,14-dihydroxycontaining products with a C22 backbone originating from DHA. Both gave essentially the same mass spectrum yet different retention times, indicating that they were very likely isomers ( Fig. 2, B and C ). These were isolated and subject to gas chromatography -mass spectrometry (GC-MS) to further identify and confi rm fragment assignments and positional sites of oxygenation, e.g., carbon positions of alcohol groups. GC-MS analyses confi rmed assigned ions from LC/MS/MS and were consistent with 7,14-dihydroxy -containing products biosynthesized from DHA ( Table I ) . Isolated human M ⌽ s incubated with 14 S -HpDHA also gave the novel 7,14dihydroxy -containing product and matched the compound from mouse M ⌽ s ( n = 3).
Novel antiinfl ammatory and proresolving mediators
In parallel with these determinations, materials obtained from mouse M ⌽ s were assessed for potential bioactivity after extraction and C18 solid-phase chromatography. M ⌽ -derived did not coelute with M ⌽ -derived products beneath labels I and II. This double dioxygenation product at a 0.1-ng dose per mouse reduced PMN infi ltration in zymosaninduced peritonitis but appeared to be less potent than the M ⌽ -isolated material ( Fig. 3 B ) . Thus, the results in Fig. 3 clearly demonstrate potent bioactions of the novel 7,14dihydroxy -containing product HPLC purifi ed from resident M ⌽ incubations with zymosan and 14 S -HpDHA.
Further experiments were performed to isolate material beneath peaks I and II ( Fig. 2 A ) and determine whether compound I is an isomer of II. Subjecting the isolated compounds to isomerization conditions ( 22 ) demonstrated that compound II likely contained a cis double bond -containing triene structure sensitive to conversion to an all-trans -containing conjugated triene (i.e., 8 E ,10 E ,12 E ) isomer I in bench and workup conditions. In view of 18 O incorporation and epoxide trapping, it is likely that the isomer I peak also contained R/S racemates at carbon 7. Further RP-HPLC purifi cation of the 7,14-dihydroxy -containing product from M ⌽ s was performed ( 20 ) and RvE1 ( 5, 6, 14 ) . Thus, these fi ndings suggested that within M ⌽ isolates obtained from cells incubated with 14 S -HpDHA, potent bioactive materials were biosynthesized from this precursor that regulated PMNs, preventing their infi ltration. These substances were likely to be very potent because only nanogram quantities given per mouse elicited antiinfl ammatory actions.
Given the ability of DHA to serve as a substrate for LOX forming both double dioxygenation products related to PD1 as well as the carbon 17 -hydroperoxide -containing precursor of epoxide ( 20 ) , we reasoned that 14 S -HpDHA might also be a substrate for double dioxygenation. This in deed proved to be the case: sequential actions of 12-LOX and 5-LOX with DHA generated 7 S ,14 S -dihydroxydocosa-4 Z ,8 E ,10 Z ,12 E ,16 Z ,19 Z -hexaenoic acid (7 S ,14 S -diHDHA; n = 5; Fig. 2 , dotted profi le; and Table I ). This is likely an isomer of the M ⌽ -isolated material ( Figs. 2 and 3 ), because this reference compound ( Fig. 2 A , dotted curve) Stereochemistries shown are tentative assignments. Double-bond geometries are shown in likely confi gurations based on proposed biosynthetic pathways. a LC-MS/MS analysis was performed with an Agilent Technologies 1100 series HPLC system coupled to an Applied Biosystems 3200 QTRAP linear ion trap quadrupole mass spectrometer equipped with an Agilent Technologies Eclipse Plus C18 column (4.6 mm × 50 mm × 1.8 μ m). The mobile phase consisted of methanol/water/acetic acid (60:40:0.01, vol/vol/vol) and was ramped to 80:20:0.01 over 7.5 min and to 95:5:0.01 over the next 4.5 min at a fl ow rate of 400 μ l/min. The fl ow rate was decreased to 200 μ l/ min for 3 min and returned to 400 μ l/min, and the mobile phase was ramped up over the next 6 min to 100:0:0.01 before returning to 60:40:0.01. b GC-MS analysis was performed with an HP6890 system (Agilent Technologies) equipped with an HP5973N mass detector. An HP-5MS column (30m × 0.25 mm × 0.25 μ m) was used with a temperature program; the initial temperature was 150 ° C, followed by 230 ° C for 8 min and 280 ° C for 10 min with a helium fl ow rate of 1 ml/min. Trimethylsilyl derivatives were prepared after treatment with diazomethane. c Spectra were recorded in methanol using an Agilent Technologies 4682 UV-Vis spectrophotometer or an Agilent Technologies 1100 series diode-array detector.
BRIEF DEFINITIVE REPORT uct (7 S ,14 S -diHDHA) was active but less potent than the new product isolated from M ⌽ s. Thus, given its potent actions and novel structure, the M ⌽ product was denoted maresin 1 (MaR1).
Maresin biosynthetic pathway
We present a hypothetical scheme for the maresin pathway (see Fig. 5 ). DHA is converted to 14-hydroperoxydocosahexaenoic acid, likely via 12-LOX in humans, as shown in incubations of DHA and 12-LOX, followed by either reduction to 14 S -HDHA and/or, via double dioxygenation (e.g., sequential 12-LOX -5-LOX), to generate 7 S ,14 S -diHDHA. In 12/15-LOX -defi cient mice, 14 S -HDHA generation in peritonitis was reduced > 95%. The key 14 S-hydroperoxide to assess its actions. The results in Fig. 3 C demonstrate that at doses as low as 0.2 ng/mouse, the new compound potently reduced infi ltration of PMNs into sites of infl ammation.
M ⌽ -enhanced phagocytosis
A key feature of a proresolving mediator, in addition to limiting PMN entry, is the dual action of stimulating M ⌽ uptake of apoptotic PMNs and/or zymosan to stimulate resolution and microbial clearance ( 4, 13, 23 ) . We determined whether the new M ⌽ -derived compound enhanced phagocytosis and compared it with RvE1, PD1, and an eicosanoid, prostaglandin E 2 (PGE 2 ; Fig. 3 D , inset) . RvE1 and PD1 are potent enhancers of M ⌽ phagocytosis at concentrations as low as 1 nM ( 13 ) . For direct comparison, the double dioxygenation prod- ( Fig. 5 ). DHA (C22:6) is an essential fatty acid and member of the omega-3 family of fatty acids, which are in high levels in marine oils. It is essential for mammalian systems in that it is not biosynthesized de novo and is therefore a nutritional requirement ( 10, 11, 21 ) . In this report, we identifi ed a novel pathway during resolution that converts DHA to new, potent bioactive products. This new pathway was identifi ed using targeted mediator lipidomics of exudates from mouse peritonitis and was demonstrated with both mouse and human M ⌽ s. Parallel biofunction and spectral analyses confi rmed the new structures as 7,14-dihydroxy -containing products biosynthesized from DHA. One of the novel products characterized, MaR1, proved to be a potent mediator, stopping PMN infi ltration and stimulating M ⌽ phagocytosis. An isomer of MaR1, 7 S ,14 S -diHDHA, was less potent, indicating stereoselective actions in vitro and in vivo. These antiinfl ammatory and proresolving actions were evident in nanogram range both in vitro and in vivo, suggesting that this new mediator pathway could play a key role in regulating catabasis or the return of tissues from the infl ammatory state to homeostasis ( 8, 13 ) .
The new compounds isolated from M ⌽ s showed distinct and separate actions on PMNs compared with mononuclear cells, such as those recently identifi ed for multifunctional mediators. Specifi cally, to expedite resolution, members of this new genus of endogenous mediators carry multilevel actions limiting further PMN accumulation at tissue sites and stimulate clearance by enhancing M ⌽ nonphlogistic phagocytosis ( 4, 23 ) . This type of selectivity places a spatial and temporal as well as a functional separation between these new mediators from, e.g., leukotrienes, which stimulate proinfl ammatory responses.
When compared with RvE1 derived from EPA and PD1/NPD1 from DHA that carries alcohol groups at carbons 10 and 17 ( 6, 7, 20, 21 ) , MaR1 proved to be of comparable potency ( Fig. 3 ) . In contrast, PGE 2 did not enhance phagocytosis, a fi nding consistent with PGE 2 and PGD 2 specifi cally reducing M ⌽ phagocytosis of apoptotic cells ( 24 ) . Although D and E series Rvs as well as PD1 share proresolving and antiinfl ammatory actions for the genus, each member acts at specific receptors ( 4, 14 ) and, thus, given the stereospecifi c actions of the new pathway mediators, it is likely that they act on their own receptors separate from those for Rvs. These fi ndings with novel chemical mediators suggest that enhancing M ⌽ capacity to remove apoptotic and necrotic cells at sites of infl ammation and enhancing microbial particle containment along with down-regulating new PMN entry to the site may not only shorten the resolution interval ( 8, 13 ) but can also protect tissues from intermediate is enzymatically converted to a 13(14)-epoxidecontaining intermediate that is then enzymatically hydrolyzed via a carbonium cation to bioactive 7,14 S -diHDHA by creating a conjugated triene within three of the six double bonds. The results from 18 O isotope incorporation using H 2 18 O demonstrated that > 75% of the oxygen at the carbon 7 position was derived from H 2 O (see Supplemental materials and methods and Fig. S1 , available at http://www.jem.org/ cgi/content/full/jem.20081880/DC1) and not from molecular oxygen, as would have been the case if this carbon 7 position alcohol group was generated by double lipoxygenation mechanism (compare with reference 20 ). In parallel, alcohol trapping with excess acidic methanol was performed with isolated M ⌽ s that gave the methoxy-trapping product 7-methoxy-14-hydroxydocosa-4 Z ,8,10,12,16 Z ,19 Z -hexaenoic acid, identifi ed using LC/MS/MS targeted profi ling. Its MS 2 spectrum showed ions consistent with acid-assisted attack at the carbon 7 position and addition of the methoxy, giving the MS 2 spectrum of m/z 373 at 10.2 min ( Fig. 4 , inset for ion assignments; and Fig. 5 ). It is also possible that a methoxy addition could have occurred at the carbon 13 position that could give essentially the same ions in MS 2 . It is more likely that methoxy addition was at carbon 7, because it is the least sterically hindered end of the conjugated carbonium cation.
To provide further confi rmation of the maresin pathway and biosynthetic scheme, isolated mouse M ⌽ s (15.5 × 10 6 cells/3 ml, 37 ° C, 30 min) were incubated with zymosan and 10 μ M of deuterium-labeled DHA-d 5 containing fi ve deuterium atoms at the 21, 21, 22, 22, and 22 carbon positions. M ⌽ s converted DHA-d 5 to 14 S -HDHA-d 5 , with diagnostic ions in its mass spectrum at m/z 348, 330, 304, 286, and 205, as well as further evidence for the 7,14 S -dihydroxy -containing product. The dihydroxy structure carried d 5 , from precursor, and was confi rmed with ions at m/z 364, 346, 320, and 302, and the hydroxy groups ' 7 and 14 positions supported by identifi ed in many systems, it remained to be determined that it can serve as a marker of DHA conversion to novel bioactive mediators. It should be noted that, in addition to 14 S -HDHA production by cells with 12-LOX, human 15-LOX can also contribute to this 14-LOX pathway because M ⌽ s and other human cells possess a prominent 12-LOX and 15-LOX ( 2, 10, 18 ), and 14 S -HDHA was essentially absent in 12/15-LOX -defi cient mice. Given the importance of platelet 12-LOX in transcellular biosynthesis of lipid mediators ( 4 ), it is likely that cell -cell interactions can also contribute to biosynthesis of maresins and related products.
Although marine omega-3 fatty acid supplements are in wide use in animals and humans because they are believed to possess therapeutic actions, convincing evidence from clinical trials supporting their actions in treating infl ammatory disorders and reducing cancer risk are not without criticism ( 29 -31 ) . Possible sources of variation in their actions in clinical studies are (a) the very high doses used (milligram to gram doses), (b) the absence of appropriate biomarkers of omega-3 fatty acid utilization, and (c) specifi c mediator functions evoked in picoto nanogram range. Thus, the new pathways and bioactive maresins documented in this report, along with Rvs, protectins, and related functional metabolome, might provide a new means to mark the impact of essential omega-3 fatty acids in health and disease, as well as provide new therapeutic approaches.
unwanted tissue injury damage and oxidative stress that can accompany infl ammation and infection.
We also found that the epoxide intermediate can undergo non enzymatic hydrolysis to give 7 R/S ,14 S -dihydroxycontaining products (which appear to coelute in this LC system) and corresponding vicinal diol, namely 13,14-diHDHA (which was isolated and identifi ed; see Fig. 5 , Table I , and Fig. S3 , available at http://www.jem.org/cgi/content/full/ jem.20081880/DC1). The proposed biosynthetic sequence is also supported by results from 18 O incorporation and deuterium (d 5 )-labeled tracking from d 5 -DHA to d 5 -labeled maresin pathway products. Collectively, these results provide evidence for a highly effi cient pathway in isolated resident M ⌽ s for the biosynthesis of potent new chemical mediators via 14-lipoxygenation of DHA and subsequent enzymatic steps ( Fig. 5 ). We also identifi ed 4,14-di-HDHA ( Table I ) , a likely product of 5-LOX and 12-LOX interactions, as well as two other new products from DHA generated by M ⌽ s, a 13(14)-epoxy-alcohol -containing docosanoid and 4 S ,13,14 Strihydroxydocosa-5,7,9,11,16 Z ,19 Z -hexaenoic acid (their bio synthesis and actions will be reported separately).
The 14 S -HDHA via arachidonate 12-LOX was fi rst identifi ed in the gills of fi sh ( 25 ) and in human platelets ( 26 ) , neural systems ( 27 ) , and many other mammalian and invertebrate marine organisms ( 28 ) . Thus, although 14 S -HDHA was pair 359.2/250.2 was used to identify 7,14-dihydroxy -containing products. Criteria for matching retention time and greater than or equal to six diagnostic ions to those of synthetic references were used for identifi cation ( 32 ) . Quantitation was performed using calibration curves constructed for each compound, and recoveries were monitored using added deuterated internal standards.
Mouse peritonitis and phagocytosis. The 7,14-dihydroxy -containing products were isolated from methyl formate fractions obtained from mouse M ⌽ s via RP-HPLC (Agilent Technologies 1100 series) using a Beckman Coulter C18 column (250 mm × 10 mm × 5 μ m) and methanol/water (65:35, vol/vol) ramped to 85:15 for 30 min. Their actions were assessed in mouse zymosan A -induced peritonitis ( 19 ) . Peritonitis was initiated by i.p. administration of 1 mg zymosan A in 1 ml of sterile saline, and each compound was administered i.v. 5 min before zymosan. At 2 h, mice were killed, and peritoneal exudates were harvested (5 ml DPBS Ϫ / Ϫ without calcium and magnesium), identifi ed, and enumerated by light microscopy and FACS. Resident M ⌽ s were identifi ed by FACS ( 8 ) . To assess proresolving actions, peritoneal M ⌽ s (24-well plate, 10 5 cells/well) from naive mice were incubated with each compound (15 min, pH 7.45), followed by the addition of FITC-labeled zymosan A for 30 min at 37 ° C. Trypan blue was used to quench extracellular zymosan particles for 1 min at 37 ° C, followed by DPBS +/+ (pH 7.45), and phagocytosis was quantifi ed using a Victor 3 (PerkinElmer).
Statistical analysis.
Results are expressed as means ± SEM. Statistical signifi cance was determined using a two-tailed Student ' s t test.
Online supplemental material. Fig. S1 shows the MS-MS spectrum of the novel product obtained with H 2 18 O and M ⌽ incubations. Fig. S2 is the representative mass spectrum of d 5 -MaR1 from M ⌽ incubation with d 5 -DHA. Fig. S3 is the GC-MS spectrum obtained for the 13,14-dihydroxy vicinal diol from DHA and M ⌽ s. This product derivative was obtained after treatment with diazomethane and BSTFA to give the methyl ester, OTMS derivative. Supplemental materials and methods describes human M ⌽ incubations, GC-MS analysis, and chiral HPLC-MS/MS. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081880/DC1. M ⌽ incubations. Resident peritoneal M ⌽ s were collected by lavage from naive mice (20 -25 g, 6 -8-wk-old FVB mice; Charles River Laboratories) with unlimited access to rodent diet 5001 (Laboratory Diet) containing EPA 1.5% and DHA 1.9% of total fatty acids ( 19 ) . All animal studies were approved and performed in accordance with guidelines provided by the Harvard Medical Standing Committee on Animals (protocol no. 02570).
After centrifugation at 2,000 rpm and addition of DPBS +/+ , M ⌽ s (15.5 × 10 6 cells/3 ml) were incubated with zymosan A and 10 μ M DHA or 14 S -HpDHA (pH 7.45) at 37 ° C for 30 min. For assessing 18 O incorporation, 0.45 ml H 2 18 O (Cambridge Isotopes) was added to 50 μ l 10 × DPBS +/+ , mixed and adjusted to approximately pH 7.3 with 1 N HCl. 5 × 10 6 isolated peritoneal M ⌽ s were suspended in H 2 18 O-containing buff er. After rapid freeze -thaw in liquid nitrogen, 5 μ M of purifi ed 14 S -HpDHA was added with 2.5 μ M A 23187 for 30 min at 37 ° C. For alcohol trapping, isolated M ⌽ s (5 × 10 6 cells/100 μ l) were incubated at 37 ° C for 5 min with 100 μ M 14 S -HpDHA and 5 μ M A 23187 , and incubations were stopped with 10 × vol of cold methanol, with the apparent pH adjusted to approximately pH 3 ( 20 ) . All other incubations were stopped with 2 vol of cold methanol and held at Ϫ 80 ° C before extraction.
Mediator lipidomics: product isolation and extractions. Deuterated internal standard (17-HDHA-d 5 , PGE 2 -d 4 ; ‫ف‬ 3 ng) was added to each incubation after protein precipitation > 30 min. Samples were extracted ( 32 ) and methyl formate fractions were taken for LC/MS/MS-based mediator lipidomics. UV spectra were recorded in methanol using an Agilent Technologies 4682 system for quantitation and assessment of structural integrity of known mediators using appropriate extinction coeffi cients ( 32 ) .
LC/MS/MS-based analysis was performed with an HPLC system (Agilent Technologies 1100 series) with a linear ion trap quadrupole mass spectrometer (3200 QTRAP; Applied Biosystems) equipped with an Eclipse Plus C18 column (4.6 mm × 50 mm × 1.8 μ m; Agilent Technologies). The instrument was run in negative ionization mode, and for enhanced product ion (EPI) mode, the mobile phase consisted of methanol/water/acetic acid (60:40:0.01, vol/vol/vol) and ramped to 80:20:0.01 over 7.5 min and to 95:5:0.01 in the next 4.5 min at a fl ow rate of 400 μ l/min. The fl ow rate was decreased to 200 μ l/min for 3 min and returned to 400 μ l/min, and the mobile phase was ramped up over the next 6 min to 100:0:0.01. For multiple reaction monitoring (MRM) data acquisition, the mobile phase was methanol/water/acetic acid (60:40:0.01) ramped to 80:20:0.01 after 5 min, 95:5:0.01 after 8 min, and 100:0:0.01 after 14 min to wash the column.
The novel dihydroxy-containing products from DHA were monitored in EPI mode (359.2). Ion pairs from reported MRM methods were used for profi ling and quantitation of 17-HDHA, 14 S -HDHA, and internal standards. Ion
